Kamada Secures Major Supply Agreement in Latin America
REHOVOT, Israel and HOBOKEN, N.J. – Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global leader in biopharmaceuticals with a renowned portfolio aimed at rare and serious conditions, proudly announces its latest achievement: securing a contract with an influential international organization.
Contract Overview
This contract pertains to the supply of two of Kamada's leading products, KAMRAB® and VARIZIG®, for a term extending from 2025 to 2027. The total projected revenue from this agreement is estimated to be around $25 million. Furthermore, the portions allocated to the fiscal year 2025 have been included in the company's recently revealed revenue guidance for that year.
Implications of the New Agreement
Amir London, Chief Executive Officer of Kamada, expressed great enthusiasm regarding this substantial agreement. He remarked that it reaffirms the global standing of their specialty immunoglobulin portfolio and bolsters the company's anticipated multi-year growth trajectory. Winning this tender exemplifies the significant commercial opportunities for Kamada’s diverse product line beyond North America.
Product Details
KAMRAB and VARIZIG are key assets in Kamada's specialty immune globulin offerings. Specifically, KAMRAB is used for the passive prevention of rabies in individuals who may have been exposed to rabid animals. In contrast, VARIZIG serves to mitigate the severity of chickenpox in vulnerable groups, such as immunocompromised patients.
About KAMRAB®
KAMRAB is a human rabies immune globulin designed for immediate post-exposure prophylaxis to protect against rabies infection. This product must be administered alongside a full rabies vaccine course to ensure top effectiveness.
Safety Profile of KAMRAB
While KAMRAB is lifesaving, it does carry some risks. Individuals may experience severe hypersensitivity reactions, including anaphylaxis. IgA-deficient patients must be particularly cautious, and availability of epinephrine is essential for immediate treatment of any severe allergic incidents. Understanding the immunological impacts, such as potential interferences with live attenuated vaccines, is crucial for providers.
About VARIZIG®
VARIZIG is categorized as Varicella Zoster Immune Globulin (Human) and is integral for high-risk patients requiring post-exposure prophylaxis against chickenpox. It is particularly vital for populations such as immunocompromised children and pregnant women to lessen the severity of the disease.
Safety Financials
As with any medication, VARIZIG must be administered with caution. There’s a risk of severe reactions in susceptible individuals, including those with known hypersensitivity. Monitoring for thrombotic events during treatment is advisable. The product’s safety profile is taken seriously and underscores the need for careful patient selection.
Kamada’s Broader Business Strategy
Kamada Ltd. remains dedicated to addressing rare and serious health conditions with innovative solutions. The company continues to expand its offerings, including six FDA-approved plasma-derived products, and has an impressive distribution network in more than 30 countries globally. Kamada is poised for significant growth, fueled by a commitment to high-quality production and the enhancement of its innovative development pipeline.
Investment in Research and Development
Alongside its commercial successes, Kamada actively invests in research to introduce new candidates into its product lineup. The company is advancing its inhaled AAT therapy aimed at treating AAT deficiency and is currently engaged in the pivotal Phase 3 InnovAATe clinical trial to evaluate this groundbreaking treatment.
Frequently Asked Questions
What is the purpose of the new supply agreement for Kamada?
The new agreement allows Kamada to supply KAMRAB® and VARIZIG® in Latin America, aiming for approximately $25 million over three years.
What are KAMRAB® and VARIZIG® used for?
KAMRAB is used for preventing rabies exposure, while VARIZIG is indicated for preventing severe chickenpox in at-risk patients.
What safety precautions should be taken with KAMRAB®?
Patients should be monitored for severe hypersensitivity reactions, and it is essential to have treatments available for such risks.
How does Kamada's distribution model work?
Kamada distributes its products directly and through strategic partners in over 30 countries, enhancing global access to critical healthcare solutions.
What is next for Kamada in research and development?
Kamada is focused on advancing new products, particularly an inhaled therapy for AAT deficiency, demonstrating its commitment to addressing unmet medical needs.
